Cryosite Limited's (ASX:CTE) Subdued P/E Might Signal An Opportunity
Jan 15
Have your own idea? Try our Stock Screener
Australian (ASX) Clinical Research and Equipment Industry Analysis
UpdatedFeb 01, 2025
DataAggregated Company Financials
Companies7
- 7D-0.9%
- 3M-23.9%
- 1Y2.4%
- YTDn/a
The Clinical Research and Equipment industry is down 3.9% over the last week with Genetic Signatures the worst performer, down 4.6%. On the other hand OncoSil Medical is actually up 20%. Over the last year, the industry has been flat overall. As for the next few years, earnings are expected to grow by 70% per annum.
Industry Valuation and Performance
Has the Australian Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 01 Feb 2025 | AU$543.1m | AU$253.8m | -AU$57,118,384.00 | 17.2x | -9.5x | 2.1x |
| Mon, 30 Dec 2024 | AU$615.8m | AU$263.5m | -AU$69,135,603.00 | 21.5x | -8.9x | 2.3x |
| Wed, 27 Nov 2024 | AU$609.3m | AU$263.5m | -AU$69,135,603.00 | 20x | -8.8x | 2.3x |
| Fri, 25 Oct 2024 | AU$697.1m | AU$263.5m | -AU$69,135,603.00 | 23.6x | -10.1x | 2.6x |
| Sun, 22 Sep 2024 | AU$663.8m | AU$263.3m | -AU$69,597,222.00 | 19.9x | -9.5x | 2.5x |
| Tue, 20 Aug 2024 | AU$639.9m | AU$246.1m | -AU$49,506,434.00 | 24.6x | -12.9x | 2.6x |
| Thu, 18 Jul 2024 | AU$652.1m | AU$246.1m | -AU$49,506,434.00 | 31.8x | -13.2x | 2.6x |
| Sat, 15 Jun 2024 | AU$547.0m | AU$246.1m | -AU$49,506,434.00 | 24.6x | -11x | 2.2x |
| Mon, 13 May 2024 | AU$504.2m | AU$246.1m | -AU$49,506,434.00 | 18.6x | -10.2x | 2x |
| Wed, 10 Apr 2024 | AU$595.9m | AU$246.1m | -AU$49,506,434.00 | 14.6x | -12x | 2.4x |
| Fri, 08 Mar 2024 | AU$542.9m | AU$246.1m | -AU$49,506,434.00 | 12.7x | -11x | 2.2x |
| Sun, 04 Feb 2024 | AU$495.2m | AU$248.2m | -AU$39,797,313.00 | 22.7x | -12.4x | 2x |
| Tue, 02 Jan 2024 | AU$543.6m | AU$248.6m | -AU$52,451,569.00 | 21x | -10.4x | 2.2x |
| Thu, 30 Nov 2023 | AU$557.4m | AU$248.6m | -AU$52,451,569.00 | 19.1x | -10.6x | 2.2x |
| Sat, 28 Oct 2023 | AU$550.8m | AU$248.6m | -AU$52,451,569.00 | 22.3x | -10.5x | 2.2x |
| Mon, 25 Sep 2023 | AU$541.3m | AU$248.6m | -AU$52,451,569.00 | 22.5x | -10.3x | 2.2x |
| Wed, 23 Aug 2023 | AU$624.9m | AU$221.2m | -AU$37,948,518.00 | 25.2x | -16.5x | 2.8x |
| Fri, 21 Jul 2023 | AU$671.2m | AU$221.5m | -AU$37,611,177.00 | 25.4x | -17.8x | 3x |
| Sun, 18 Jun 2023 | AU$634.3m | AU$221.5m | -AU$37,611,177.00 | 24.4x | -16.9x | 2.9x |
| Tue, 16 May 2023 | AU$622.5m | AU$221.5m | -AU$37,611,177.00 | 28.7x | -16.6x | 2.8x |
| Thu, 13 Apr 2023 | AU$701.1m | AU$221.7m | -AU$39,169,534.00 | 28.3x | -17.9x | 3.2x |
| Sat, 11 Mar 2023 | AU$775.3m | AU$221.7m | -AU$39,169,534.00 | 29x | -19.8x | 3.5x |
| Mon, 06 Feb 2023 | AU$823.6m | AU$184.6m | -AU$29,264,632.00 | 33x | -28.1x | 4.5x |
| Wed, 04 Jan 2023 | AU$768.8m | AU$184.6m | -AU$29,264,632.00 | 34x | -26.3x | 4.2x |
| Fri, 02 Dec 2022 | AU$772.3m | AU$184.6m | -AU$29,264,632.00 | 34x | -26.4x | 4.2x |
| Sun, 30 Oct 2022 | AU$755.3m | AU$184.6m | -AU$29,264,632.00 | 28.4x | -25.8x | 4.1x |
| Tue, 27 Sep 2022 | AU$794.2m | AU$184.6m | -AU$29,264,632.00 | 32.6x | -27.1x | 4.3x |
| Thu, 25 Aug 2022 | AU$903.2m | AU$175.0m | -AU$30,461,039.00 | 50.4x | -29.7x | 5.2x |
| Sat, 23 Jul 2022 | AU$879.0m | AU$150.4m | -AU$31,222,532.00 | 26.3x | -28.2x | 5.8x |
| Mon, 20 Jun 2022 | AU$838.6m | AU$150.4m | -AU$31,222,532.00 | 28.9x | -26.9x | 5.6x |
| Wed, 18 May 2022 | AU$1.0b | AU$150.2m | -AU$30,481,316.00 | 25.5x | -33.3x | 6.8x |
| Fri, 15 Apr 2022 | AU$1.2b | AU$150.2m | -AU$30,481,316.00 | 20.8x | -37.7x | 7.7x |
| Sun, 13 Mar 2022 | AU$1.1b | AU$167.1m | -AU$90,069,489.00 | 19.1x | -12.1x | 6.5x |
| Tue, 08 Feb 2022 | AU$1.5b | AU$138.2m | -AU$84,243,063.00 | 113x | -18x | 11x |
Price to Earnings Ratio
-18x
Current Industry PE
- Investors are pessimistic on the Australian Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 3.7x is higher than the industry's current PS ratio of 2.1x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have improved over the last three years.
- Revenues for these companies have grown 22% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Comparison
How does Australian Clinical Research and Equipment compare with similar industries?
| AU Market | 1.42% | |
| Healthcare | 2.71% | |
| Life Sciences | -0.87% | |
| Clinical Research and Equipment | -0.87% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| OSL OncoSil Medical | AU$0.006 | 20.0% +AU$4.5m | -25.0% | PS17.2x | |
| MEM Memphasys | AU$0.007 | 16.7% +AU$1.8m | -22.2% | PS11.4x | |
| CTE Cryosite | AU$0.74 | 3.5% +AU$1.2m | 13.7% | PE19.8x |